Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum
Cullinan Therapeutics (NASDAQ:CGEM) expects 2026 to be a catalyst-heavy year across its pipeline, led by two high-priority T-cell engager programs in autoimmune disease and acute myeloid leukemia...